Xcout IntelSign inSubscribe

Illumina

0J8ZBiotechSan Diego, United States

Illumina, Inc. specializes in delivering advanced sequencing and array technologies designed for genetic and genomic examination. These offerings cater to a diverse array of markets, fostering the widespread use of genomic insights across both research laboratories and clinical environments. Key application areas include life sciences, cancer diagnostics, reproductive medicine, agricultural science, and various nascent fields. The company's portfolio encompasses specialized instrumentation and associated consumables vital for genetic analysis. Additionally, it offers comprehensive genotyping and sequencing services, extends instrument maintenance contracts, and engages in development and licensing partnerships, alongside providing cancer screening services. Illumina's client base is extensive, comprising genomic research facilities, universities, state-funded laboratories, and healthcare providers. It also serves pharmaceutical firms, biotechnology companies, commercial molecular diagnostics providers, and businesses focused on consumer genomics. Globally, Illumina distributes its products through direct sales channels in North America, Europe, Latin America, and the Asia-Pacific. Furthermore, it leverages third-party life-science distributors to reach markets across Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.

Subscribe to see Illumina’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

Illumina at a glance

Illumina is a biotech company headquartered in San Diego, United States. It is publicly listed (0J8Z) with a market capitalisation of $28.1B. Xcout tracks 20 named people at Illumina, including Jacob Thaysen (CEO, Interim Chief Commercial Officer & Director). Xcout recorded 4 job postings from Illumina in the last 90 days.

Industry
Biotech
Headquarters
San Diego, United States
Market cap
$28.1B
Employees
8,600
Ticker
0J8Z
Job postings recorded (90 days)
4

Illumina leadership

  • Jacob ThaysenCEO, Interim Chief Commercial Officer & Director
  • Stephanie CamposPresident
  • Ankur DhingraChief Financial Officer
  • Steven BarnardChief Technology Officer
  • Kevin Carl PegelsChief of Global Operations
  • Mark FieldChief Information Officer

14 more named people on record for Illumina, with roles, board committees and tenure — see the full roster →

Hiring at Illumina

Xcout recorded 4 job postings from Illumina in the last 90 days, from a hiring record Xcout has kept since June 2026.

The weekly hiring trend, the roles and locations behind it — see Illumina's hiring signals →

Illumina competitors

A few of Illumina's closest competitors — see the full list of competitors and alternatives →

Bionano Genomics, Inc.BNGO · BiotechSan Diego, United States
70% matchPublic

Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.

Market cap$16.8M
Employees96
Bionano Genomics, Inc. competitors & alternatives →
RevvityRVTY · Life Sciences, DiagnosticsWaltham, United States
67% matchPublic

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

Market cap$12.3B
Employees11,000
JavaScriptReact
Revvity competitors & alternatives →

Get Illumina's news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

Illumina — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on Illumina in Xcout Intel

  • 20 named people with titles, LinkedIn and board committees
  • Weekly hiring history and the mix of roles behind it
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →